Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (AKBA) on September 12 and set a price target of $6.00. The company’s shares closed last Monday at $2.70, close to its 52-week low of $2.46.
According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.7% and a 33.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Akebia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.86, which is a 165.9% upside from current levels. In a report issued on August 31, Piper Sandler also maintained a Buy rating on the stock with a $18.00 price target.
See today’s analyst top recommended stocks >>
Based on Akebia Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $88.48 million and GAAP net loss of $60.75 million. In comparison, last year the company earned revenue of $101 million and had a GAAP net loss of $58.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More on AKBA:
